Neoplasmata Clinical Trial
— NICT-NIPT-CAOfficial title:
Non Invasive Cancer Test (NICT): a Proof of Principle Study.
| NCT number | NCT03019471 |
| Other study ID # | NL55080.068.15 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | March 2016 |
| Est. completion date | December 2024 |
The investigators aim to collect tumor DNA out of blood of cancer patients. If this is successful this could lead to the development of a cancer test in blood in the future, which is less invasive than current diagnostic methods.
| Status | Recruiting |
| Enrollment | 40 |
| Est. completion date | December 2024 |
| Est. primary completion date | March 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer, non-small cell lung cancer and anaplastic glioblastoma, before start of radiation therapy, chemoradiation or chemotherapy. 2. Patients age > 18 years, willing and able to comply with the protocol as judged by the investigator with a signed informed consent Exclusion Criteria: 1. Patients with a history of malignant disease other than the disease under study, with an exception for adequately treated squamous cell carcinoma of the skin, basal cell carcinoma of the skin and in situ cervix carcinoma. 2. Pregnancy |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Maastricht University Medical Center | Maastricht | Limburg |
| Lead Sponsor | Collaborator |
|---|---|
| Maastricht University Medical Center |
Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | ctDNA | Demonstrate the presence or absence of ctDNA in patients plasma. Examine if there us a sufficient concentration of ctDNA in the plasma to reliably diagnose cancer and determine the CNV | One year |